GC
NAVB

Guggenheim Capital’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Guggenheim Capital’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,510
Closed -$18K – 2749
2018
Q1 		$18K Buy
2,510
+15
+0.6% +$112 ﹤0.01% 2752
2017
Q4 		$18K Sell
2,495
-311
-11% -$2.63K ﹤0.01% 2677
2017
Q3 		$23K Buy
2,806
+139
+5% +$1.18K ﹤0.01% 2740
2017
Q2 		$27K Hold
2,667
– – ﹤0.01% 2768
2017
Q1 		$31K Buy
2,667
+171
+7% +$1.94K ﹤0.01% 2754
2016
Q4 		$31K Hold
2,496
– – ﹤0.01% 2823
2016
Q3 		$46K Buy
+2,496
New +$31.6K ﹤0.01% 2772
2016
Q1 		– Sell
-745
Closed -$20K – 3035
2015
Q4 		$20K Buy
745
+62
+9% +$2.15K ﹤0.01% 2918
2015
Q3 		$31K Sell
683
-287
-30% -$10.8K ﹤0.01% 2871
2015
Q2 		$31K Buy
970
+80
+9% +$2.32K ﹤0.01% 2980
2015
Q1 		$28K Buy
890
+39
+5% +$1.32K ﹤0.01% 2976
2014
Q4 		$32K Buy
851
+75
+10% +$2.06K ﹤0.01% 2948
2014
Q3 		$20K Sell
776
-47
-6% -$1.24K ﹤0.01% 2965
2014
Q2 		$24K Buy
823
+168
+26% +$5.43K ﹤0.01% 3153
2014
Q1 		$24K Sell
655
-71
-10% -$2.69K ﹤0.01% 3214
2013
Q4 		$30K Buy
+726
New +$28.4K ﹤0.01% 3101
2013
Q3 		– Sell
-559
Closed -$30K – 3217
2013
Q2 		$30K Buy
+559
New +$27.9K ﹤0.01% 2951

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Guggenheim Capital's NAVB Position: Q2 2018 in Review

Guggenheim Capital sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2018, closing a stake of 2,510 shares — an estimated $18K sold.

Guggenheim Capital first reported a position in NAVB in Q2 2013 and held it in 17 quarters. The position peaked at $46K in Q3 2016. 54 funds tracked by Wall St. Rank hold NAVB as of Q2 2018.

  • Guggenheim Capital reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 2,510 Navidea Biopharmaceuticals Inc. shares in Q2 2018, an estimated $18K.
  • Guggenheim Capital first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 17 quarters.
  • Guggenheim Capital's Navidea Biopharmaceuticals Inc. position peaked at $46K in Q3 2016.
  • 54 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.